Hypo-Stream Ltd

Using phylogenetics as a guide, Hypo-Stream has investigated the phylogenetically conserved Innate Immune Response (IIR) to discover the lead asset "M3", which originated as an agent for homeostasis. M3 is one of several and the most potent evolutionary successor to antibiotics. Our research team discovered broad spectrum antimicrobial action without resistance (including WHO list of AMR pathogens of concern) & multimodal anti-inflammatory action via functional neutralisation of Il-6, TNF-a and Il-10. + modulation of the Dublin-Boston ratio (seen as critical in ARDS and scar amelioration). Hypo-stream holds multiple granted patents in global territories for the pharmaceutical use of our compounds along with Orphan designation in a High value clinical use. CHMP from EMA confirms Phase III ready with an EMA orphan designation. Lead asset in orphan class burns, conflict and military trauma / gun-shot / IED trauma flash-burns.